Keywords: Sanofi, MS, Aubagio, Multiple sclerosis, Ph III, Indian vaccine plant, Genzyme, Shantha

Sanofi oral MS drug Aubagio shows strong efficacy in Ph III trial; plans massive Indian vaccine plant

Article | 07 October 2011

Print This

French drug major Sanofi (Euronext: SAN) and its subsidiary Genzyme says that the results of a pivotal Phase III TEMSO ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in